Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Dec / On to New Pastures
Business & Regulation Standards & Regulation Business & Trends Facilities & Equipment Technology & Manufacturing

On to New Pastures

Dutch authorities hand over the keys to the EMA’s new HQ in the heart of Amsterdam’s financial district

By Maryam Mahdi 12/10/2019 1 min read Quick Read (pre 2022)

Share

The UK’s Brexit referendum in 2016 has caused uncertainty for many businesses in the pharma sector. For the EMA, it meant relocation from London to a more secure spot in the European Union. Since March 2019, the EMA has been operating from a temporary site, the Spark building, in Amsterdam Sloterdijk. But now, a purpose-built 19 storey building in Amsterdam’s Zuidas area is ready for action. Constructed in under two years, the completion of the new HQ met the EMA’s November deadline.

“I actually love the time pressure. It is an amazing challenge to build an office in such a short period of time. Something like this would usually take twice as long,” said Frans Rombouts, Project Director at Heijmans, the construction-services company that took on the build . “On March 8, we started working on the design – a phase that generally takes over eight months; our final design was finished in half a year – an unprecedented achievement in the Netherlands.”

Guido Rasi, the EMA’s Executive Director, who recently signed the lease, thanked the Dutch authorities for supporting the agency’s goal of finishing construction by November, but reflected on the broader challenges of the move in an interview with Agence France Presse (1). “The move was painful. It was painful because it was a choice to move to London, and this came out of the blue. [Our staff] had to find jobs for spouses, schools [for their children, and adapt to] a different way of living."

Though the building doesn’t overlook Amsterdam’s famous canals, it does boast a 38,000m2 floor space, a rooftop terrace, and a vertical garden. The building exceeds the “excellent” rating of BREEAM (a sustainability assessment method that is used to masterplan projects, infrastructure and buildings) and has a Bijna EnergieNeutraal Gebouw (BENG – nearly zero-energy building) performance, meaning that at least 50 percent of the energy used in the building comes from sustainable sources. 

The 900 staff who will call the new site home should officially begin working there in January 2020, once all technical equipment has been installed. During the transition from the Spark building to the Zuidas site, the EMA says it will limit the number of face-to-face meetings.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. France 24, “Dutch flaunt Brexit booty with EU agency opening”. Available at: http://bit.ly/2Lg4EZl.

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Regulators Target Ebola
Standards & Regulation
Regulators Target Ebola

December 1, 2014

0 min read

Will FDA fast review and voucher incentives make a difference?

Safety First - Sizing Up Biologics Side Effects
Standards & Regulation Biosimilars
Safety First - Sizing Up Biologics Side Effects

December 2, 2014

0 min read

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.